Abstract:The authors regret that an error was made in the detail for affiliation c. The correct affiliation is: Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. The authors would like to apologise for any inconvenience caused. Re: Pathologic complete responses, long-term outcomes, and recurrence patterns in HER2-low vs. HER2-zero breast cancer after neoadjuvant chemotherapy: Several issues about HER2 expression and neoadjuvant chemotherapy in breast cancerEuropean Journal of CancerVol. 180PreviewWe followed with interest the report by Sora Kang et al. that pathological complete response (pCR) rate and disease-free survival (DFS) in patients with HER2-low as well as HER2-0 breast cancers who have undergone neoadjuvant chemotherapy [1]. There are many complex factors influencing condition of response and survival of breast cancer after neoadjuvant therapy by the changes of HER2 and hormone receptor (HR) status. We appreciated the authors' work in comparing the prognosis of patients with breast cancer after neoadjuvant chemotherapy in different HER2 status and providing new therapeutic ideas. Full-Text PDF

Corrigendum to “evaluation of a Whole Process Management Model Based on an Information System for Cancer Patients with Pain: A Prospective Nonrandomized Controlled Study” [Asia-Pacific J Oncol Nurs 9 (2022) 88–96]

Corrigendum to “effects of a Symptom Management Intervention Based on Group Sessions Combined with a Mobile Health Application for Persons Living with HIV in China: A Randomized Controlled Trial” [int J Nurs Sci 8 (2021) 370–379]

Corrigendum to “Knowledge of Opioid-induced Respiratory Depression Among Chinese Healthcare Professionals: A Cross-Sectional Study” [Asia-Pacific J Oncol Nursing 9 (2022) 55–60]

Corrigendum: Validation of the GALAD model and establishment of a new model for HCC detection in Chinese patients

Corrigendum to “Efficacy and Safety of Butorphanol Use in Patient-Controlled Analgesia: A Meta-Analysis”

Corrigendum to “ARMCX Family Gene Expression Analysis and Potential Prognostic Biomarkers for Prediction of Clinical Outcome in Patients with Gastric Carcinoma”

Corrigendum to "Digital exclusion and functional dependence in older people: findings from five longitudinal cohort studies" eClinical Medicine 54 (2022) 101708

Corrigendum: A Prognostic Model Based on Immune-Related Long Non-Coding RNAs for Patients With Cervical Cancer

Corrigendum to: Progress of Angiogenesis Signal Pathway and Antiangiogenic Drugs in Nasopharyngeal Carcinoma

Corrigendum to ‘Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics’ [Genes & Diseases10 (2023) 1367–1401]

Corrigendum to 'Effective strategies to enhance the diagnosis and treatment of RCC: The application of biocompatible materials' [Mater. Today Bio 27 (2024) 101149]

Corrigendum to "re: Pathologic Complete Responses, Long-Term Outcomes, and Recurrence Patterns in HER2-low Vs. HER2-zero Breast Cancer after Neoadjuvant Chemotherapy: Several Issues about HER2 Expression and Neoadjuvant Chemotherapy in Breast Cancer" [eur J Cancer 180 (2023) 184-185].

Corrigendum to "Gene mutations in newly diagnosed multiple myeloma patients detected by next-generation sequencing technology" [ Cancer Pathog Ther. 2024;2:205-211]

Corrigendum: Knowledge and thresholds for palliative care and surgery among healthcare providers caring for adults with serious illness

Corrigendum to "Potential pre-COPD indicators in association with COPD development and COPD prediction models in Chinese: a prospective cohort study" [The Lancet Regional Health - Western Pacific 44 (2024) 100984].

Corrigendum: Delayed Diagnosis and Treatment of Cancer Patients During the COVID-19 Pandemic in Henan, China: an Interrupted Time Series Analysis

Corrigendum to “Yokukansan Alleviates Cancer Pain by Suppressing Matrix Metalloproteinase-9 in a Mouse Bone Metastasis Model”

Corrigendum: Potential Mechanisms of Action of Chinese Patent Medicines for COVID-19: A Review

Corrigendum: Neoadjuvant Tislelizumab Combined with Chemotherapy in Locally Advanced Oral or Oropharyngeal Squamous Cell Carcinoma: a Real-World Retrospective Study.

Corrigendum: Progression-free survival and time to progression as potential surrogate endpoints for overall survival in chemoradiotherapy trials in limited-stage small-cell lung cancer: A systematic review and meta-analysis

Corrigendum: Exercise for reducing chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis of randomized controlled trials